<DOC>
	<DOCNO>NCT02293603</DOCNO>
	<brief_summary>To determine safety profile CAP-1002 administer multi-vessel intracoronary infusion subject DCM . The study explore safety exploratory efficacy endpoints CAP-1002 .</brief_summary>
	<brief_title>Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells ( DYNAMIC )</brief_title>
	<detailed_description>Eligible subject undergo sequential intracoronary infusion CAP-1002 placebo three coronary artery supply three major cardiac territory heart ( anterior , lateral , inferior/posterior ) . After completion screening procedure , Phase Ia subject receive CAP-1002 administer via intracoronary infusion dose escalation , stepwise manner . Phase Ia subject follow Week 2 Months 1 , 2 , 3 , 6 12 CAP-1002 infusion . The first fourteen ( 14 ) subject receive intracoronary infusion CAP-1002 open-label fashion ( Phase Ia ) . Once 14 subject Phase Ia reach primary safety endpoint ( 1 month visit ) , DSMB conduct review Phase Ia data recommend whether proceed enrollment next 28 subject Phase Ib .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Cardiomyopathy , Dilated</mesh_term>
	<criteria>Major 1 . DCM leave ventricular ejection fraction ( LVEF ) ≤ 35 % determined historical TTE within previous 6 month 2 . New York Heart Association ( NYHA ) Class III ambulatory Class IV heart failure 3 . Use evidence base medicaltherapy ( betablockers , ACEinhibitors/angiotensin receptor blocker , aldosterone antagonist ) without devicetherapy ( Implantable cardioverterdefibrillator cardiac resynchronizing therapy ) , accordance ACC/AHA guideline management heart failure , least three month prior enrollment document contraindication intolerance patient preference 4 . Coronary anatomy suitable Investigational Product ( IP ) infusion , determine Eligibility Committee ( team cardiology expert ) 5 . Ability provide inform consent followup protocol procedures 6 . Screening cardiac CT leave ventriculogram ejection fraction &lt; 40 % leave ventricular dilatation 7 . Age ≥ 18 year Major 1 . Diagnosis active myocarditis 2 . Immunologic incompatibility available Master Cell Banks ( MCBs ) singleantigen bead ( SAB ) serum antibody profile 3 . Left Ventricular Assist Devices ( LVAD ) actively process acquire one 4 . Recent placement cardiac pacemaker and/or resynchronization pace therapy within past three month actively process acquire one 5 . History sustain ventricular tachycardia ( VT ) require cardiopulmonary resuscitation ( exception subject subsequently receive ICD ) 6 . Noncardiovascular disease life expectancy &lt; 3 year 7 . Known hypersensitivity contrast agent 8 . Estimated glomerular filtration rate ( GFR ) &lt; 50 mL/min 9 . Active infection responsive treatment 10 . Active allergic reaction , connective tissue disease autoimmune disorder 11 . History cardiac tumor , cardiac tumor demonstrate screen 12 . History previous stem cell therapy 13 . History treatment immunosuppressive agent , include chronic systemic corticosteroid , biologic agent target immune system , antitumor antineoplastic drug antivascular endothelial growth factor ( VEGF ) within 6 month prior enrollment ( include drug elute coronary stent ) 14 . History receipt chemotherapeutic agent know implicated cardiac dysfunction [ Adriamycin , trastuzumab ( Herceptin ) ] 15 . Known moderatesevere aortic stenosis/insufficiency severe mitral stenosis/regurgitation 16 . Participation ongoing protocol study experimental drug device 17 . Current active alcohol drug abuse inability comply protocolrelated procedure 18 . Pregnant/nursing woman woman childbearing potential without use active highly reliable contraception 19 . Known history Human Immunodeficiency Virus ( HIV ) infection 20 . Known history chronic viral hepatitis 21 . Abnormal liver function ( serum glutamic pyruvic transaminase ( SGPT ) &gt; 10 time upper reference range ) and/or abnormal hematology ( hematocrit &lt; 25 % , white blood cell ( WBC ) &lt; 3000 µl , platelet &lt; 100,000 µl ) study without reversible , identifiable cause 22 . Evidence tumor screen chest/abdominal/pelvic ( body ) CT scan 23 . Any prior organ transplant 24 . Being actively list , active consideration ( i.e. , workup ) , solid organ transplant kind 25 . Known hypersensitivity bovine product 26 . Known hypersensitivity dimethyl sulfoxide ( DMSO ) 27 . Any malignancy within past 2 year ( except insitu nonmelanoma skin cancer insitu cervical cancer ) 28 . Any prior radiation therapy/treatment chest 29 . Uncontrolled diabetes ( HbA1 &gt; 9.0 ) 30 . Any condition reason , opinion Investigator Medical Monitor , would render subject unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>cardiomyopathy</keyword>
	<keyword>cardiosphere-derived stem cell</keyword>
	<keyword>intracoronary infusion</keyword>
	<keyword>adult stem cell</keyword>
	<keyword>heart disease</keyword>
	<keyword>ventricular dysfunction</keyword>
	<keyword>pathological process</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>heart failure</keyword>
</DOC>